Compare CETX & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CETX | SLRX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.6M |
| IPO Year | 1998 | N/A |
| Metric | CETX | SLRX |
|---|---|---|
| Price | $4.27 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 4.8M |
| Earning Date | 12-29-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,095,551.00 | N/A |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $15.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.50 | N/A |
| 52 Week Low | $2.50 | $0.71 |
| 52 Week High | $55.50 | $108.00 |
| Indicator | CETX | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 28.98 |
| Support Level | $2.50 | $0.81 |
| Resistance Level | $9.70 | $0.92 |
| Average True Range (ATR) | 0.96 | 0.08 |
| MACD | 0.24 | 0.11 |
| Stochastic Oscillator | 25.00 | 60.88 |
Cemtrex Inc is a multi-industry technology company. It has expanded in a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security system. The company's operating segment includes, Security segment, Industrial Services segment and the corporate segment. The security segment provides end to end security to all industrial, corporate and governmental security via owned subsidiary Vicon. Whereas AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment. It geographically operates in USA, UK and India, with maximum of revenue from USA.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.